Life Sciences

Citation Growth Corp. is a well-established high quality cannabis producer in North America, owning licensed cultivation property in Nevada, Washington, California, and British Columbia. Citation Growth Corp. pairs premier seed genetics and organic growing techniques, with plans to utilize and expand its proprietary growing technology/techniques to all its facilities and operations. The end goal is to become a true Multi-State Operator (MSO) that is fully integrated from seed to sale.

Cognetivity Neurosciences Ltd. is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA) for use in medical and commercial environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain, potentially allowing early diagnosis of dementia. Cognetivity aims to develop the ICA through planned clinical studies to the market in North America and Europe.

Cresco Labs, based in Chicago is a grower, processor and retailer of premium cannabis with operations in six states (Illinois, Ohio, Pennsylvania, Nevada, California and Arizona) and approval pending for acquisitions in three more states (New York, Massachusetts, Maryland). The company focuses on entering markets with outsized demand potential, significant supply constraints and high barriers to entry. Its speed-to-market gives Cresco a competitive advantage as it replicates its model to expand its national footprint. Cresco’s ability to execute is complemented by a brand strategy that is tailored to all major consumer segments: everyday cannabis, medicinally focused, connoisseur grade, and chef inspired edibles by James Beard Award-winning pastry chef Mindy Segal. Learn more about Cresco Labs at crescolabs.com.

(Note: In addition to the 110,355,953 Subordinate Voting Shares that are listed and trading, there are 184,857,074 Subordinate Voting Shares reserved for issuance pursuant to pending acquisitions, the redemption and conversion rights attached to: (i) the Proportionate Voting Shares of Cresco Labs Inc.; and (ii) certain outstanding securities of Cresco Labs, LLC, which is a subsidiary of Cresco Labs, Inc. The total number of Subordinate Voting Shares as converted is 295,213,027, inclusive of options, options reserved for issuance and warrants.)

DionyMed is a multi-state, vertically integrated operating platform that designs, develops, markets and sells a portfolio of branded cannabis products. DionyMed also provides distribution, logistics and value-added manufacturing services on behalf of cannabis cultivators, distributors, processors and retailers. DionyMed’s operations are currently located in California and Oregon.

Investor Note: In addition to the 30,234,859 Subordinate Voting Shares that are listed and trading, there are 28,678,400 Subordinate Voting Shares reserved for issuance pursuant to the conversion rights attached to other classes of equity shares that are issued and outstanding but not listed. The total number of issued  shares assuming all are converted into the listed class would be 58,913,259.